In 2012 I was giving a talk on cardiovascular health and I mentioned that I had serious concerns about statins. Back in 1965 Dr Michael DeBakey, the father of Cardiovascular surgery, had the same concerns. Why would we want to lower cholesterol when it is involved in everything from memory to hormone manufacture, from cell wall structure to arterial repair? New research shows those concerns are still an issue but will they be heard?
Cholesterol-lowering statin drugs could be doing more harm than good,
and should be abandoned as the primary therapy for heart disease
prevention, a major review by researchers at University College Hospital
in Galway has concluded.
Instead, Coenzyme Q10, an antioxidant, was found to be more effective
at controlling cholesterol and preventing heart disease, which has
fewer, or no side effects and is available from most health food stores.
Statins dramatically increase the risk of diabetes and cataracts in
younger patients, and cancer and neuro-degenerative diseases in the
elderly. And the researchers say that the benefits don’t outweigh the
risks. Even for patients with advanced heart disease, the drugs may
extend life by just a further nine months at best if the drug is taken
for 30 years.
Analysing previous studies on statins, the researchers discovered
that some had never been published because the results were so alarming,
while others had obscured the real risks. One study, the Illuminate
trial, was shelved after researchers discovered the statin drug
increased the risk of cancer and sudden death. Unfortunately, this
latest research is unlikely to be heard in the mainstream media because
the statin market is worth £20bn a year and rising.
Source: Source: Journal of Endocrine and Metabolic Diseases, 2013; 3: doi: 10.4236/ojemd.2013.33025